The oxidized phospholipid PGPC impairs endothelial function by promoting endothelial cell ferroptosis via FABP3

J Lipid Res. 2024 Feb;65(2):100499. doi: 10.1016/j.jlr.2024.100499. Epub 2024 Jan 11.

Abstract

Ferroptosis is a novel cell death mechanism that is mediated by iron-dependent lipid peroxidation. It may be involved in atherosclerosis development. Products of phospholipid oxidation play a key role in atherosclerosis. 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) is a phospholipid oxidation product present in atherosclerotic lesions. It remains unclear whether PGPC causes atherosclerosis by inducing endothelial cell ferroptosis. In this study, human umbilical vein endothelial cells (HUVECs) were treated with PGPC. Intracellular levels of ferrous iron, lipid peroxidation, superoxide anions (O2•-), and glutathione were detected, and expression of fatty acid binding protein-3 (FABP3), glutathione peroxidase 4 (GPX4), and CD36 were measured. Additionally, the mitochondrial membrane potential (MMP) was determined. Aortas from C57BL6 mice were isolated for vasodilation testing. Results showed that PGPC increased ferrous iron levels, the production of lipid peroxidation and O2•-, and FABP3 expression. However, PGPC inhibited the expression of GPX4 and glutathione production and destroyed normal MMP. These effects were also blocked by ferrostatin-1, an inhibitor of ferroptosis. FABP3 silencing significantly reversed the effect of PGPC. Furthermore, PGPC stimulated CD36 expression. Conversely, CD36 silencing reversed the effects of PGPC, including PGPC-induced FABP3 expression. Importantly, E06, a direct inhibitor of the oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine IgM natural antibody, inhibited the effects of PGPC. Finally, PGPC impaired endothelium-dependent vasodilation, ferrostatin-1 or FABP3 inhibitors inhibited this impairment. Our data demonstrate that PGPC impairs endothelial function by inducing endothelial cell ferroptosis through the CD36 receptor to increase FABP3 expression. Our findings provide new insights into the mechanisms of atherosclerosis and a therapeutic target for atherosclerosis.

Keywords: Atherosclerosis; CD36; Endothelial function; Fatty acid binding protein-3; Oxidized lipids; PGPC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis*
  • Cyclohexylamines*
  • Endothelium / metabolism
  • Fatty Acid Binding Protein 3
  • Ferroptosis*
  • Glutathione / metabolism
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Iron / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Phenylenediamines*
  • Phospholipid Ethers / metabolism
  • Phospholipid Ethers / pharmacology
  • Phospholipids
  • Phosphorylcholine

Substances

  • Phospholipids
  • ferrostatin-1
  • Phosphorylcholine
  • Phospholipid Ethers
  • Glutathione
  • Iron
  • FABP3 protein, human
  • Fatty Acid Binding Protein 3
  • Cyclohexylamines
  • Phenylenediamines